Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

210 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities.
Stacchiotti S, Frezza AM, Blay JY, Baldini EH, Bonvalot S, Bovée JVMG, Callegaro D, Casali PG, Chiang RC, Demetri GD, Demicco EG, Desai J, Eriksson M, Gelderblom H, George S, Gounder MM, Gronchi A, Gupta A, Haas RL, Hayes-Jardon A, Hohenberger P, Jones KB, Jones RL, Kasper B, Kawai A, Kirsch DG, Kleinerman ES, Le Cesne A, Lim J, Chirlaque López MD, Maestro R, Marcos-Gragera R, Martin Broto J, Matsuda T, Mir O, Patel SR, Raut CP, Razak ARA, Reed DR, Rutkowski P, Sanfilippo RG, Sbaraglia M, Schaefer IM, Strauss DC, Sundby Hall K, Tap WD, Thomas DM, van der Graaf WTA, van Houdt WJ, Visser O, von Mehren M, Wagner AJ, Wilky BA, Won YJ, Fletcher CDM, Dei Tos AP, Trama A. Stacchiotti S, et al. Among authors: von mehren m. Cancer. 2021 Aug 15;127(16):2934-2942. doi: 10.1002/cncr.33618. Epub 2021 Apr 28. Cancer. 2021. PMID: 33910263 Free PMC article.
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H. Demetri GD, et al. Among authors: von mehren m. N Engl J Med. 2002 Aug 15;347(7):472-80. doi: 10.1056/NEJMoa020461. N Engl J Med. 2002. PMID: 12181401 Free article. Clinical Trial.
Routine mammography is associated with earlier stage disease and greater eligibility for breast conservation in breast carcinoma patients age 40 years and older.
Freedman GM, Anderson PR, Goldstein LJ, Hanlon AL, Cianfrocca ME, Millenson MM, von Mehren M, Torosian MH, Boraas MC, Nicolaou N, Patchefsky AS, Evers K. Freedman GM, et al. Among authors: von mehren m. Cancer. 2003 Sep 1;98(5):918-25. doi: 10.1002/cncr.11605. Cancer. 2003. PMID: 12942557 Free article.
Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.
Heinrich MC, Corless CL, Blanke CD, Demetri GD, Joensuu H, Roberts PJ, Eisenberg BL, von Mehren M, Fletcher CD, Sandau K, McDougall K, Ou WB, Chen CJ, Fletcher JA. Heinrich MC, et al. Among authors: von mehren m. J Clin Oncol. 2006 Oct 10;24(29):4764-74. doi: 10.1200/JCO.2006.06.2265. Epub 2006 Sep 5. J Clin Oncol. 2006. PMID: 16954519 Clinical Trial.
Soft tissue sarcoma.
Demetri GD, Baker LH, Benjamin RS, Casper ES, Conrad EU 3rd, D'Amato GZ, DeLaney TF, Ettinger DS, Heck R Jr, Heslin MJ, Hutchinson RJ, Jacobs CD, Kiel K, Kraybill WG, Letson GD, O'Donnell RJ, Paz IB, Pfeifer J, Pollock RE, Randall RL, Sasson AR, Schupak KD, Tyler DS, von Mehren M, Wayne J; National Comprehensive Cancer Network. Demetri GD, et al. Among authors: von mehren m. J Natl Compr Canc Netw. 2007 Apr;5(4):364-99. doi: 10.6004/jnccn.2007.0034. J Natl Compr Canc Netw. 2007. PMID: 17442230 No abstract available.
NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.
Demetri GD, Benjamin RS, Blanke CD, Blay JY, Casali P, Choi H, Corless CL, Debiec-Rychter M, DeMatteo RP, Ettinger DS, Fisher GA, Fletcher CD, Gronchi A, Hohenberger P, Hughes M, Joensuu H, Judson I, Le Cesne A, Maki RG, Morse M, Pappo AS, Pisters PW, Raut CP, Reichardt P, Tyler DS, Van den Abbeele AD, von Mehren M, Wayne JD, Zalcberg J; NCCN Task Force. Demetri GD, et al. Among authors: von mehren m. J Natl Compr Canc Netw. 2007 Jul;5 Suppl 2:S1-29; quiz S30. J Natl Compr Canc Netw. 2007. PMID: 17624289 Review.
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.
Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, Blackstein ME, Blanke CD, von Mehren M, Brennan MF, Patel S, McCarter MD, Polikoff JA, Tan BR, Owzar K; American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team. Dematteo RP, et al. Among authors: von mehren m. Lancet. 2009 Mar 28;373(9669):1097-104. doi: 10.1016/S0140-6736(09)60500-6. Epub 2009 Mar 18. Lancet. 2009. PMID: 19303137 Free PMC article. Clinical Trial.
Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules.
Demetri GD, Chawla SP, von Mehren M, Ritch P, Baker LH, Blay JY, Hande KR, Keohan ML, Samuels BL, Schuetze S, Lebedinsky C, Elsayed YA, Izquierdo MA, Gómez J, Park YC, Le Cesne A. Demetri GD, et al. Among authors: von mehren m. J Clin Oncol. 2009 Sep 1;27(25):4188-96. doi: 10.1200/JCO.2008.21.0088. Epub 2009 Aug 3. J Clin Oncol. 2009. PMID: 19652065 Clinical Trial.
Other targetable sarcomas.
Pires de Camargo V, van de Rijn M, Maestro R, de Alava E, Madoz-Gúrpide J, Pilotti S, von Mehren M, Pedeutour F, Maki RG, Rutkowski P, Thomas DM. Pires de Camargo V, et al. Among authors: von mehren m. Semin Oncol. 2009 Aug;36(4):358-71. doi: 10.1053/j.seminoncol.2009.06.008. Semin Oncol. 2009. PMID: 19664496 Review.
210 results